Andrew Carry Kruegel

This inventor holds 15 USPTO granted patents and 28 published patent applications and 3 EPO patents. Top assignees: Columbia University, Gilgamesh Pharmaceuticals, Inc., Research Foundation for Mental Hygiene, Inc.. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Carry Kruegel. Retrieved from https://idiyas.com/inventor/andrew-carry-kruegel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 28)

% Patents Active = 93.3

EPO Patents = 3 (Patent Applications = 18)

Average Co-Inventor Count = 2.6

ph-index = 4

Forward Citations = 30(Granted Patents)

Location History:

New York, NY (US) (2018 - 2023)
Secaucus, NJ (US) (2020 - 2024)

Company Filing History:

Gilgamesh Pharmaceuticals, Inc.

patents

1 out of 45

Research Foundation for Mental Hygiene, Inc.

patents

4. 1 out of 519

Sloan-Kettering Institute for Cancer Research

patents

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12534425 - Phenalkylamines and methods of treating mood disorders (2026-01-27),

2. 12195478 - Opioid receptor modulators (2025-01-14),

3. 12180158 - Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amine (2024-12-31),

4. 12157722 - Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine (2024-12-03),

5. 12129234 - Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine (2024-10-29),

6. 11912707 - Mitragynine alkaloids as opioid receptor modulators (2024-02-27),

7. 11840541 - Opioid receptor modulators (2023-12-12),

8. 11787772 - Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists (2023-10-17),

9. 11760758 - Mitragynine analogs for the treatment of pain, mood disorders and substance use disorders (2023-09-19),

10. 11440879 - Methods of treating mood disorders (2022-09-13),

11. 11344510 - Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders (2022-05-31),

12. 10961244 - Mitragynine alkaloids as opioid receptor modulators (2021-03-30),

13. 10844027 - Carboxylic diarylthiazepineamines as mu-opioid receptor agonists (2020-11-24),

14. 10183919 - Class of mu-opioid receptor agonists (2019-01-22),

15. 9988377 - Small molecule inducers of GDNF as potential new therapeutics for neuropsychiatric disorders (2018-06-05),

Sure! Here is an article about inventor Andrew Carry Kruegel:

Title: Andrew Carry Kruegel - Pioneering Innovations in Pharmaceutical Compounds

Introduction:

Andrew Carry Kruegel, a renowned inventor based in Secaucus, NJ, has carved a niche for himself in the field of pharmaceutical compounds with his groundbreaking innovations. With a total of 10 patents to his name, Kruegel continues to push the boundaries of medical science and drug development.

Latest Patents:

Kruegel's latest patents include "Mitragynine alkaloids as opioid receptor modulators" and "Opioid receptor modulators." These patents introduce new compounds for the treatment of pain, depressive disorders, mood disorders, and anxiety disorders, showcasing Kruegel's commitment to addressing pressing healthcare challenges.

Career Highlights:

Throughout his career, Kruegel has made significant contributions to the field of pharmaceuticals. He has worked with esteemed institutions such as Columbia University in the City of New York and Gilgamesh Pharmaceuticals, Inc., where his expertise and innovative thinking have led to groundbreaking discoveries.

Collaborations:

Kruegel has collaborated with talented individuals in his field, including Dalibor Sames and Jonathan A Javitch. These collaborations have not only enriched his own work but have also paved the way for interdisciplinary approaches in pharmaceutical research.

Conclusion:

In conclusion, Andrew Carry Kruegel stands as a beacon of innovation in the realm of pharmaceutical compounds. His patented inventions and collaborative efforts underscore his passion for advancing medical science and improving patient outcomes. With a promising future ahead, Kruegel continues to inspire and drive progress in the pharmaceutical industry.

Profile summary based on public USPTO records.